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Abstract
Summary Osteoporotic fractures may pose a challenge for
skeletal regeneration. This study investigates if pharmaceuti-
cal interventions such as bone morphogenetic protein 7
(BMP-7) alone or in combination with Zoledronate have
equivalent efficacy in osteoporotic bone? Our findings sug-
gest they do and that an osteoporotic bone environment may
increase sensitivity to BMP-7.
Introduction Osteoporosis is thought to contribute to delayed
or impaired bone healing. Bone morphogenetic protein 7
(BMP-7) alone or synergistically combined with zoledronate
(ZA) has proven effective in augmenting the regenerative re-
sponse in healthy young male rats. Yet their comparative effi-
cacy in an osteoporotic bone environment is unknown. Our
study aimed to answer the following questions using the
ovariectomized (OVX) rat model of osteoporosis: Do osteo-
porotic fractures pose a greater challenge for skeletal regener-
ation? Are interventions with BMP-7-alone or combined with
ZA of equivalent efficacy in osteoporotic bone?
Methods Sham operations (n = 33) or ovariectomies (n = 34)
were performed in 12-week-old female Sprague-Dawley rats.
Mid-diaphyseal open femoral osteotomies were created at
24 weeks of age and the rats allocated to either (i) untreated,
(ii) BMP-7-only or (iii) BMP-7 + ZA treatment groups. At
6 weeks post-osteotomy, fracture healing was evaluated by
radiography, μCT and 3-point bending mechanical tests.
Results Cumulatively, radiological, micro-structural and me-
chanical measures were equivalent in both healthy and osteo-
porotic environments. A reduced response to BMP-7-alone
was observed in healthy rats that may be age/gender- or
protocol/fracture-model dependent. Conversely, the BMP-7-
only treated OVX group attained 100 % union in addition to
significantly increased measures of mineralized bone volume,
total callus volume, peak force and absorbed energy relative to
untreated OVX fractures.
Conclusions Our findings refute the hypothesis that osteopo-
rotic fractures constitute a greater recalcitrant challenge for
skeletal regeneration. Furthermore, our results suggest that
an oestrogen-deficient environment may in fact cause an in-
creased sensitivity to BMP-7.
Keywords Bmp-7 . Fracture healing . Osteoporosis .
Ovariectomy . Zoledronate
Introduction
Osteoporosis, a common metabolic bone disorder character-
ized by increased bone fragility, predisposes individuals to be
more susceptible to fractures and is thought to contribute to
recalcitrant fracture healing [1]. Much effort has been devoted
to unravelling the aetiology of osteoporosis and, in particular,
reversing the slide toward bone fragility through the preserva-
tion of bone mass. Surprisingly, less focus has been devoted to
the potential impairment or diminution of the fracture healing
process in the presence of osteoporosis [2].
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Successful fracture repair is an orchestrated cascade of cel-
lular and molecular events following a distinct temporal and
spatial template, which culminates in the regeneration of bone,
remodelling of the fracture site and restoration of function.
Critical to the success of this skeletal regeneration process is
the condition of the bone environment as characterized by its
biological viability and biomechanical stability. Impairment in
the form of age- or pathophysiology-related degradation and
severity of trauma may lead to delayed or aborted osseous
union, and sometimes necessitates interventions to specifical-
ly enhance the fracture healing process, in addition to stabiliz-
ing the fracture. Osteoporosis certainly impacts the severity
and frequency of fractures but a definitive consensus is absent
on its impact on the repair process. Some studies of ovariec-
tomized (OVX) rats have reported an impaired healing pro-
cess characterized by reduced callus bone formation, delayed
or prolonged endochondral ossification and delayed callus
remodelling [3–11]. Although frequently cited, these studies
have shown inconsistent or contradictory results.
Moreover, evidence of osteoporosis-related anomalies at
the molecular and cellular level have been reported that might
have implications for the ability of bone to repair itself. Local
gene expression studies have documented significantly lower
expression levels of transcription factors critical to osteo-
blastogenesis such as runt-related transcription factor 2
(RUNX-2) and Osterix (Osx) and decreased expression of
the bone formation marker Osteocalcin [12, 13].
Furthermore, the ratio of the expressions of the pro-
osteoclastogenic factor RANKL to the anti-osteoclastogenic
factor OPG was significantly higher in osteoporotic samples
indicative of a diminished capacity in mediating osteoclasto-
genesis [12–14].
Clinically, there are too few studies or comparisons of frac-
ture repair in healthy and osteoporotic individuals to substan-
tiate the view that osteoporotic fractures constitute a recalci-
trant challenge [2]. Certainly, fixation failure in osteoporotic
fractures presents complications with significantly increased
rates of non-unions/implant failure, post-operative mal-align-
ments and revision surgeries [15, 16]. Furthermore, the in-
verse correlation between bone mineral density and fixation
strength or anchorage is well documented and thus failure or
poor functional outcomes are not unexpected [17]. However,
fixation failure is not equivalent to impaired fracture
healing but is a consequence of poor bone quality and does
not per se mean there is a decline in the bone regenerative
capacity. Despite the absence of conclusive clinical evi-
dence, it can be postulated that the physiological repair
process is impaired or altered on the basis of the sparse
literature that exists [12, 13, 18–22].
Fracture non-unions are rare, and although osteoporosis
affects metaphyseal bone more than diaphyseal, non-unions
are predominantly found in diaphyseal bones in the elderly
osteoporotic population, like the femur or the humerus. In
instances of fracture non-unions, the healing process could
be augmented through the use of potent anabolic agents such
as bone morphogenic protein 7 (BMP-7), alone or synergisti-
cally combined with anti-catabolic agents such as the bisphos-
phonate zoledronate (ZA) [23]. BMPs are powerful
osteoinductive stimulators of new bone formation and are crit-
ical to the osteoregenerative process in promoting the terminal
differentiation of committed osteoblastic precursors and osteo-
blasts from progenitor mesenchymal cells and osteoprogenitors
[24, 25]. Multifunctional in nature, BMPs also modulate oste-
oclastogenesis and osteoclast homeostasis via the RANKL/
RANK molecular mechanism or via direct stimulation of oste-
oclastic activity [23]. Consequently, the potential for premature-
ly induced bone and callus resorption has been documented
[26]. To counter the upregulated catabolic response, this has
necessitated the use of antiresorptives in conjunction with
BMPs to optimize the anabolic potency of BMPs.
Antiresorptive bisphosphonates such as ZA are primarily used
in the treatment of osteoporosis for preservation of bone mass
through promotion of osteoclast apoptosis [27].
Pharmacological interventions such as these should be
based on the understanding of the bone environment and the
influence of the environment on treatment efficacy. Use of
BMP-7 alone or in combination with ZA has proven to sub-
stantially increase callus formation and enhance fracture
healing in healthy young male rats [23, 28, 29]. Yet their
efficacy in an osteoporotic bone environment or in older fe-
male rats remains unclear [30]. The consequences of an im-
balance that favours bone resorption in an osteoporotic bone
environment compounded with the upregulated catabolism of
BMP-7 may portend as-yet-unknown complications to the
fracture healing process. Therefore, the current study aimed
to answer the following questions in a recalcitrant open-
fracture model: Does the diminished biological viability of
the osteoporotic bone environment pose a greater challenge
for skeletal regeneration? And if so, are interventions with
BMP-7 alone or in combination with ZA of equivalent effica-
cy in osteoporotic bone?
Materials and methods
Experimental model
Female Sprague-Dawley rats (Charles River, Germany) at
12 weeks of age either underwent ovariectomy (n = 34) or
were sham-operated (n = 33). Using this model, we have pre-
viously established the presence of extensive structural dete-
rioration characteristic of ovariectomy-induced osteoporosis
at multiple anatomical sites in the 18 weeks following ovari-
ectomy [31]. Consequently, at 24 weeks of age, mid-
diaphyseal osteotomies were created in the right femur of all
rats in accordance with a previously described open fracture
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model of recalcitrant non-unions [29, 32]. This model leads to
approximately 50 % non-unions at the 6-week time point in
young healthy male rats [29, 32]. The rats were randomly
allocated to one of six treatment groups: (i) Control (untreat-
ed), (ii) OVX (untreated), (iii) Control (BMP-7 only), (iv)
OVX (BMP-7 only), (v) Control (BMP-7 + ZA) and (vi)
OVX (BMP-7 + ZA). Animals were maintained on ad libitum
access to food and water, housed in pairs and permitted unre-
stricted weight bearing. In line with the fracture model proto-
col, the rats were euthanized at 6 weeks post-osteotomy.
Approval of laboratory animal care and experimental protocol
was obtained from the institutional animal ethics and scientific
advisory committee (Ethical Permission No. M 316-11).
Surgery and drug administration
A putty was made by mixing 2 mg of BMP-7 in 570 mg
bovine collagen (Osigraft, Stryker Biotech, Malmö, Sweden)
with 200 mg carboxymethyl cellulose (CMC) and appor-
tioned in 50 μg doses [23]. Anaesthesia was induced through
intraperitoneal injection of a solution constituting saline, diaz-
epam (2.5 mg/mL) and pentobarbital-natrium (15 mg/mL).
Transverse femoral osteotomies at the mid-diaphysis were
created using an oscillating power saw and the fractures were
stabilized and fixed with an intramedullary K-wire [32].
Treatments were subsequently administered based on group
allocation. The putty was placed circumferentially around the
osteotomy and the muscle fascia closed by running sutures to
contain the putty before the skin was closed. At 2 weeks fol-
lowing surgery, the rats received a single subcutaneous injec-
tion of either saline or ZA (0.1 mg/kg) (Zometa, Novartis,
North Ryde, NSW, Australia). The 0.1 mg/kg dosage of ZA
administered is approximately equivalent on a milligramme to
kilogramme basis to a once yearly dose received by humans
for the treatment of osteoporosis. At 6 weeks post-osteotomy
(30 weeks of age), the rats were sacrificed by an intraperito-
neal injection of pentobarbital sodium. Body weight at time
point of sacrifice was 314 ± 29 g and 420 ± 36 g for sham-
operated and ovariectomized rats, respectively (p < 0.001).
Postmortem, the osteotomized femurs and the intact contralat-
eral femurs were harvested and all K-wires extracted.
Radiographs
Antero-posterior radiographs of all femurs were obtained
using a clinical X-ray system (GE Healthcare Discovery,
Fairfield, CT, USA). Degree of fracture union was visually
assessed blinded by an orthopaedic surgeon. It was classified
as either demonstrating (1) complete healing (remodelled frac-
ture gap with callus bridging both medially and laterally and
no visible fracture line), (2) complete union (callus bridging
both medially and laterally but with visible fracture line), (3)
partial union (callus bridging either medially or laterally) or
(4) non-union.
Quantitative micro-computed tomography
Fracture sites of the femurs were imaged with Skyscan 1172
microCT system (v. 1.5, Skyscan, Aarteselaar, Belgium),
using an isotropic voxel size of 15 μm. Tomographic image
acquisition was conducted with X-ray source settings of
100 kV/100 μA, 8–10 repeated scans and the use of a
0.5 mm aluminium filter. Image reconstruction (NRecon
Skyscan, v 1.5.1.4) included corrections for ring artefacts
and beam hardening.
The volume enclosed by a proximal and distal distance of
±1.5 mm from the fracture line was defined as the boundaries
of the region of interest (ROI). Analysis of ROIs consisted of
quantification of the total callus volume, highly mineralized
bone volume, bone volume fraction (BV/TV) inside the callus
and average tissue mineral density using custom morphomet-
ric scripts written in MATLAB (v 8.50 (R2015a) Mathworks,
Massachusetts, USA). Calibration phantoms of calcium hy-
droxyapatite with densities of 0.25 and 0.75 g/cm3 and a water
phantom were scanned and reconstructed in accordance with
the manufacturers’ protocol. Highly mineralized tissue
corresponded to bone mineral densities greater than a thresh-
old of 0.642 g/cm3 and poorly mineralized tissue was defined
as densities in the threshold range between 0.410 and 0.642 g/
cm3 [33]. Grayscale values corresponding to these thresholds
were identified based on the calibrated reference densities.
3-Point bending tests
All fractured femurs and corresponding contralateral femurs
were tested in 3-point bending (Instron 8511 load frame, High
Wycombe, UK/MTS TestStar II controller, Minneapolis,
USA). With the fracture line of the callus positioned directly
under the central loading point, the femurs were subject to a
preload of 10 N at a rate of 0.1 mm/s, allowed to adapt for 10 s
whereupon they were loaded until failure at a constant rate of
1.0 mm/s. Peak force, extrinsic stiffness and absorbed energy
were calculated from the recorded load-displacement curves.
Statistics
Statistical analysis was performed using the Mann-WhitneyU
test for testing significant differences between Control and
OVX groups and between treatment groups for all measure-
ment parameters (SPSS, v22, SPSS Inc.). Differences in me-
chanical properties between fracture and contralateral control
femurs were tested using the Wilcoxon signed rank test.
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Results
Radiographs
Radiological healing rates were similar between Control
and OVX groups across all treatment groups (Table 1). In
untreated rats, more than half of fractures resulted in non-
union with healing rates of 43 and 44 % observed in
Control and OVX rats, respectively. In three of the four
treatment groups which included BMP-7, radiological
healing was observed in all (100 %) rats whereas with
the BMP-7 only treated Control group a 70 % success
rate was observed.
Quantitative micro-computed tomography
Total callus volume was significantly greater in BMP-only
treated OVX rats compared to BMP-only treated Control
(non-OVX) rats (p < 0.001) (Table 2, Fig. 1). However,
no significant differences in mineralized bone volumes
were present in comparisons of Control and OVX rats
irrespective of treatment. In BMP-only and BMP + ZA
treated groups, bone volume fraction (BV/TV) was signif-
icantly lower in OVX rats than Control rats (p < 0.01,
p < 0.001). Other noteworthy distinctions between
Control and OVX rats include a significantly lower aver-
age tissue mineral density in the latter in the BMP-only
treatment groups (p < 0.05).
Furthermore, in comparisons between treatments, min-
eralized bone volumes were significantly augmented in
the BMP + ZA groups compared to all other treatment
groups irrespective of bone condition (p < 0.01;
p < 0.001) (Table 3, Fig. 1). In measures of total callus
volume, the response to treatments differed between
Control and OVX rats. Callus volumes were larger in
BMP + ZA treated Control rats relative to all other treat-
ment groups (p < 0.01; p < 0.001). In contrast, both BMP-
only and BMP + ZA treated OVX rats exhibited increases
in callus volumes relative to untreated rats (p < 0.001).
Comparisons of callus cross-sections in BMP-only treated
femurs revealed distinctly different structures in Control
and OVX rats. Notably, the larger calluses in OVX rats
were characterized by thin callus walls enclosing sparse
trabecular architecture (Supplementary material). This is
reflected in the BV/TV parameter which is significantly
lower in BMP-only treated OVX fractures compared with
untreated or BMP + ZA treated OVX fractures (p < 0.01;
p < 0.001).
Noteworthy also, were the increased presence of sig-
nificant differences between OVX treatment groups than
between Control treatment groups (Table 3). In compari-
sons of untreated and BMP-treated OVX rats, significant-
ly higher measures of total callus volume (p < 0.001) and
highly mineralized bone volume (p < 0.05) were ob-
served in the latter group but these differences were no-
tably absent in the corresponding Control groups
(Table 3, Fig. 2).
3-Point bending tests
Non-unions were excluded in the analysis of mechanical
parameters. No significant differences were noted in the
mechanical properties of Control and OVX groups for all
treatments (Table 2). Across treatment groups, BMP +
ZA outperformed all others groups in terms of peak
force, extrinsic stiffness and absorbed energy (Table 3).
Furthermore, BMP + ZA generated peak force and
absorbed energy values that were similar to the values
obtained for the contralateral control femurs (Fig. 3). In
comparison, untreated fractures and BMP-treated frac-
tures recorded significantly diminished peak force and
extrinsic stiffness values relative to the corresponding
contralateral femurs (p < 0.05; p < 0.01). Absorbed en-
ergy values between fracture and non-fracture femurs
were also significantly lower in the untreated groups
and the BMP-treated Control group (p < 0.05) but the
Table 1 Radiographic scoring of healing at 6 weeks post-fracture based on radiographs of the fracture site
All Unions All unions
(1) + (2) + (3)
(4) Non-union








Untreated Control 14 2/14 3/14 1/14 6/14 (43 %) 8/14 (57 %)
Untreated OVX 16 – 5/16 2/16 7/16 (44 %) 9/16 (56 %)
BMP Control 10 – 4/10 3/10 7/10 (70 %) 3/10 (30 %)
BMP OVX 10 5/10 5/10 – 10/10 (100 %) –
BMP + ZA Control 9 6/9 1/9 2/9 9/9 (100 %) –
BMP + ZA OVX 8 3/8 5/8 – 8/8 (100 %) –
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difference was not of statistical significance in the BMP-
treated OVX group.
Discussion
The objective of the present study was to analyse the regener-
ative capacity of osteoporotic bone and to assess the efficacy
of pharmaceutical interventions in enhancing this capacity
using an established ovariectomized rat model of osteoporo-
sis. Literature on osteoporotic fracture repair is contradictory
with publications suggesting either impairment at the early
stages of fracture healing, impairment at the late stages of
fracture healing or no impairment of the healing process.
Our findings demonstrate the fracture healing capacity in an
oestrogen-deficient environment to be equivalent to that in
healthy bone in all three treatment groups in a long bone
model of recalcitrant healing.
Fractures in ovariectomized rats are no more recalcitrant
than fractures in non-ovariectomized rats
Cumulatively, our findings suggest that at 6 weeks post-
osteotomy, OVX fractures appear to be no more recalcitrant
than equivalent healthy fractures. The efficacy of the treat-
ments is retained in the osteoporotic bone environment, if
not surpassed in the case of BMP-7 only. Across radiological,
micro-structural and mechanical measures of bone quality, the
impaired biological viability and biomechanical stability of
OVX-induced osteoporotic bone does not appear to adversely
impair the fracture repair process.
The literature, which is mainly limited to OVX rat
studies, is far from conclusive with findings both
supporting and contradicting the hypothesis that osteopo-
rotic fractures constitute a greater recalcitrant challenge.
Namkung-Matthai et al. used an open fracture model and
reported diminished measures of callus cross-sectional
area, bone mineral density (BMD) and biomechanical
properties at 3 weeks post-osteotomy relative to healthy
controls [3]. Decreased callus widths and callus areas at
early fracture healing time points and a reversed trend of
increased callus areas at late time points were reported
by both Shi et al. and Hao et al. [4, 5]. Their findings
are suggestive of a healing process characterized by re-
duced bone formation and delayed callus remodelling.
Hao et al. documented inferior microarchitecture param-
eters and callus bone mineral density across weeks 4, 8
and 12 following osteotomy and diminished biomechan-
ical properties at week 12 [5]. Furthermore, the results of
Chung et al. supported the notion of delayed callus re-
modelling based on their measures of the ratio of the
bone remodelling markers osteoprotegrin (OPG) and
RANKL which was lower at weeks 4 and 8 in OVX rats
[6]. The findings of Islam et al. are also suggestive of a
potential prolongation in the healing process with the
authors noting a sustained endochondral ossification
Table 2 Micro-structural parameters based on micro-computed tomographic images and mechanical three-point bending data. Statistical comparison






p-valueControl OVX Control OVX Control OVX
(N = 14) (N= 16) (N = 10) (N = 10) (N= 9) (N = 8)
Total Callus Volume (mm3) Mean 54.1 57.3 63.5 122.1 *** 101 126.5
SD 15.4 12.3 19.0 24.3 29.2 29.6
High Mineralized Bone Volume (mm3) Mean 27.8 25.5 33.7 34.6 61.5 62.8
SD 14.0 9.4 6.4 5.2 15.0 18.2
Low Mineralized Bone Volume (mm3) Mean 7.5 6.9 5.7 6.5 14.3 17.7
SD 3.2 1.7 1.7 1.6 6.6 6.8
Bone Volume Fraction (%) Mean 49.6 44.0 54.8 28.9 *** 61.8 49.6 **
SD 16.2 12.8 8.5 4.4 5.2 7.7
Tissue Mineral Density (g/cm3) Mean 0.99 1.01 1.20 1.15 * 1.08 1.05
SD 0.22 0.20 0.06 0.05 0.11 0.04
(N = 6) (N= 7) (N = 7) (N = 10) (N= 9) (N = 8)
Peak Force (N) Mean 83.1 60.5 80.8 96.1 178 177
SD 32.6 20.9 28.4 26.0 62.2 95.0
Extrinsic Stiffness (N/mm) Mean 175.5 74.0 108.0 97.3 239 160
SD 90.1 71.3 64.1 53.9 123 63.2
Absorbed Energy (N mm) Mean 18.8 26.5 31.1 54.5 87.1 138
SD 9.9 13.8 11.9 24.3 40.1 120
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phase characterized by elevated expression of BMP-2
and TNF-α and increased numbers of predominantly os-
teoclasts but also osteoblasts and TNF-α + cells in OVX
rats [7]. Together, these studies suggest a decline in the
capacity for fracture repair in osteoporotic fractures,
characterized by decreased callus formation, delayed or
prolonged endochondral ossification and delayed or di-
minished callus remodelling.
Conversely, the literature also contains publications, re-
markably overlooked, that document no differences or only
marginal differences in the healing processes of healthy and
OVX rats. Using an open fracture model, Cao et al. examined
healing at 6 weeks and 16 weeks following fracture induction
and observed no effects of osteoporosis in their evaluations of
bone callus area, bone mineral content (BMC), moment of
inertia, biomechanical properties and intrinsic material prop-
erties at either time point [34]. Likewise, Wheeler et al. report-
ed no differences in peak bending force and stiffness in com-
parison of OVX and control rats at weeks 4, 6 and 8 following
fracture [35]. Kubo et al., also using an open fracture model,
found no differences at 6 weeks post-osteotomy and reported
decreases in BMD and histological distinctions but compara-
ble mechanical properties at 12 weeks post-osteotomy [36].
Notably, callus widths did not significantly differ at 6 or
12 weeks. Shi et al. observed only marginal discrepancies in
microarchitecture parameters at weeks 2, 4 and 8 and no dif-
ferences in mechanical properties at week 8 [4]. Similarly,
McCann et al. documented no significant differences in radio-
logical healing at weeks 1, 2 and 4 in an open fracture model
[11]. And although the authors reported radiological healing
to differ at weeks 6 and 8, this was not evident in their mea-
sures of mechanical strength at weeks 6 and 8.
Of relevance in the interpretation of the findings in these
studies is the significance of age, anatomical site and time
post-ovariectomy in determining the extent of osteoporotic
deterioration of the bone environment. And consequently,
comparisons between studies are somewhat problematic. In
general, studies which reported differences in healing featured
animals that were older at ovariectomy. Neither the time be-
tween ovariectomy and fracture creation nor the type of frac-
ture model (i.e. open or closed) appeared to clearly influence
the outcome. Nevertheless, collectively, the published pre-
clinical studies and clinical studies have yet to formulate a
compelling and conclusive argument for the recalcitrant na-
ture of osteoporotic fractures. And our results are in agreement
with this.
Does an oestrogen-deficient environment increase
sensitivity to BMP-7?
Our findings indicate that the osteogenic response with BMP-
only treatment is different in healthy and osteoporotic bone
environments. BMP-only treated OVX fractures exhibited larg-
er calluses equivalent in volume to those achieved with BMP +
ZA (Table 3). Notably mineralized bone volumes were unaf-
fected since the calluses were characterized by thin walls and
sparse trabecular architecture (Supplementary material). This
was not necessarily detrimental to healing, since no significant
differences were observed in the mechanical parameters be-
tween BMP-treated Control and OVX groups (Table 2).
OVX-induced osteoporosis is characterized by high bone turn-
over and it can be speculated that the large callus volumes are a
product of the upregulated anabolism of OVX coupled with the
potent anabolic effect of BMP-7. Similarly, the augmented cat-
abolic consequences of OVX and BMP-7 yield the sparse
microarchitecture within the calluses.
Noteworthy also was the response in healthy rats where
BMP-7 alone was not as beneficial as expected when com-
pared to untreated fractures. Based on radiographic healing,
untreated fractures attained a union rate of 43 % and BMP-7
treated fractures attained a union rate of 70 %. Indeed, across
microstructural and mechanical measures, treatment with
BMP-7 alone did not prove to be of much benefit when com-
pared to untreated control rats. Conversely, the OVX group
achieved 100 % radiological union in addition to significantly
increased measures of mineralized bone volume, total callus
Fig. 1 MicroCT reconstruction of the cross-section of the fracture site for
a representative sample based on the median total callus volume sample
from each group to illustrate the influence of the treatments on callus
microarchitecture (ParaView, v3.1, Kitware Inc.)
702 Osteoporos Int (2017) 28:697–707
volume, peak force and absorbed energy relative to their un-
treated OVX counterparts (Fig. 2).
It should be noted that comparisons of union rates between
groups in this study are not sufficiently powered to detect
significant differences. However, the fact that BMP-7 alone
did not achieve 100 % radiological union in Control rats is
surprising since our previous studies of BMP-7 in combina-
tion with bone autograft or allograft in young male rats
achieved 100 % radiological unions at 6 weeks [28, 29] and
a segmental defect model using BMP-7 alone achieved a sim-
ilar result at 8 weeks [23]. Moreover, using the same fracture
model in 7–8 week old healthy male rats, a 100 % union rate
was also observed with BMP-7 at 6 weeks in one of our
ongoing, unpublished studies.
Of relevance when interpreting the findings of fracture
healing studies is the predisposition to often use younger, male
animals compared to the current study. Much of the pre-
clinical studies on the osteoinductive potency of recombinant
BMP-7 were demonstrated in rabbit, canine, ovine and non-
human primate models of diaphyseal critical-sized segmental
defects [37–40]. Furthermore, these findings have been cor-
roborated by clinical studies that have produced comparable
results to autograft based on assessments of radiological
healing and functional outcomes [38, 41]. To the best of our
knowledge, the age or gender dependent efficacy of BMP-7 is
yet to be investigated. Gender discrepancies in the physiolog-
ical and pathophysiological mechanisms underlying ageing
and osteoporosis exist. For instance, Föger-Samwald et al.
reported no significant differences in local gene expression
of the osteoclast related genes RANKL and OPG between
elderly men with age-related osteoporosis and elderly men
with osteoarthritis [42]. In a follow-up study, the authors re-
ported a significantly increased ratio of RANKL to OPG in
elderly osteoporotic women relative to age-matched control
cohort of elderly women [13]. Thus, the age or gender depen-
dency of BMP-7 is a valid question.
Unlike the segmental defect models, non-union models
pose a different challenge as the potential for spontaneous
Table 3 Micro-structural parameters based on micro-computed tomographic images and mechanical three-point bending data. Statistical comparison
based on Mann-Whitney U test between treatment groups
Control OVX
Untreated BMP BMP + ZA Untreated BMP BMP + ZA
Total callus volume (mm3) Mean 54.1 63.5 101 57.3 122.1 126.5
SD 15.4 19.0 29.2 12.3 24.3 29.6
p value *** oo *** ***
High mineralized bone volume (mm3) Mean 27.8 33.7 61.5 25.5 34.6 62.8
SD 14.0 6.4 15.0 9.4 5.2 18.2
p value *** ooo * *** ooo
Low mineralized bone volume (mm3) Mean 7.5 5.7 14.3 6.9 6.5 17.7
SD 3.2 1.7 6.6 1.7 1.6 6.8
p value ** oo *** oo
BV/TV (%) Mean 49.6 54.8 61.8 44.0 28.9 49.6
SD 16.2 8.51 5.23 12.8 4.44 7.67
p value o ** ooo
Tissue mineral density (g/cm3) Mean 0.99 1.20 1.08 1.01 1.15 1.05
SD 0.22 0.06 0.11 0.20 0.05 0.04
p value * oo oo
Peak force (N) Mean 83.1 80.8 178 60.5 96.1 177
SD 32.6 28.4 62.2 20.9 26.0 95.0
p value ** oo * ** o
Extrinsic stiffness (N/mm) Mean 175.5 108 239 74.0 97.3 160
SD 90.1 64.1 123 71.3 53.9 63.2
p value o * o
Absorbed energy (N mm) Mean 18.8 31.1 87.1 26.5 54.5 138
SD 9.9 11.9 40.1 13.8 24.3 120
p value *** ooo * ** o
*p < 0.05; **p < 0.01; ***p < 0.001 when compared to untreated femurs and o p < 0.05, oo p < 0.01, ooo p < 0.001 when compared to BMP only treated
femurs
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healing is present and the role of BMPs is to augment this
response. In this study, this was not the response in healthy
rats. A review of the literature was not able to uncover studies
of the effectiveness of BMP-7 in a non-union model in healthy
rats that is independent of other osteo-stimulatory agents such
as grafts or scaffolds. Conversely, if indeed there is perturba-
tion in osteoporotic bone of the processes governing the frac-
ture healing process (which is not necessarily inhibitory), our
findings suggest that the presence of BMP-7 is significantly
beneficial. There is some evidence to suggest the involvement
of BMPs in the pathogenesis of osteoporosis [43]. And if so, it
could be asserted that when the spontaneous healing process is
fully functional, the effect of BMP-7 is diminished.
Nevertheless, the sensitivity of BMP-7 in healthy and os-
teoporotic older female rats remains to be clarified and it is
undoubtedly valid to question if our findings are an age/
gender-dependent characteristic or strictly a model-related or
protocol-related consequence. Moreover, BMP-7 induced
bone formation is indeed pleiotropic in nature with a suscep-
tibility to fracture site variation in terms of the local
mechanical environment, pH, extent of vascularization, size
of the hematoma, release kinetics, surgical technique and local
population of connective tissue progenitor cells [44]. Thus
further investigation is warranted.
BMP + ZA is by far the most effective treatment
but potentially longer recovery due to delayed remodelling
is expected
Finally, the effectiveness of BMP-7 + ZA irrespective of
whether the underlying bone was healthy or osteoporotic fur-
ther validates adoption of the anabolic—anti-catabolic para-
digm in optimizing pharmacological interventions. Complete
union in all samples was observed at 6 weeks, in addition to
dramatically increased callus and mineralized bone volumes
and the mechanical strength parameters of peak force and
absorbed energy attaining values equivalent to that of the con-
tralateral femurs. However, this is expected to be potentially
offset by delayed remodelling of the callus and delayed callus
maturation [45]. And with regard to functional outcomes, it
Fig. 2 Radiological union rates,
microstructural parameters based
on micro-computed tomographic
images and mechanical three-
point bending data of healthy and
osteoporotic fractures treated with
BMP-7 alone. Statistical
comparison based on Mann-
Whitney U test of the osteogenic
response of healthy and
osteoporotic fractures to treatment
with BMP-7 alone. (*p < 0.05;
***p < 0.001)
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may prove to be problematic if the substantial callus formed is
present for an extended length of time.
Limitations
The current study is not without its limitations, most notably
the presentation of results at a single time point. The use of a
single time point at 6 weeks post-osteotomy was justified in
the context of the number of groups involved and that it allows
comparisons of outcomes with our previous publications
reporting results from the non-union model at the same time
point. In addition, the analysis of mechanical properties does
not account for the disparity in body weight between Control
and OVX groups (100 g difference). Finally, the choice of a
diaphyseal model to study osteoporotic fractures could be
questioned with the majority of the fractures being
metaphyseal. However, the aim of the study was primarily to
test whether BMP can be used to treat or prevent diaphyseal
non-unions as effectively in older osteoporotic animals as pre-
viously shown in younger animals.
Conclusion
Our findings refute the hypothesis that OVX fractures consti-
tute a greater recalcitrant challenge for skeletal regeneration.
Treatment with BMP-7 alone or synergistically with ZAwas
of equivalent efficacy or better in an osteoporotic bone envi-
ronment. Contrary to expectations, the response to BMP-7
alone was limited in healthy rats. Earlier pre-clinical fracture
healing studies of BMP-7 have predominantly used younger,
male animals and segmental defect models. Thus a potential
age/gender or fracture model dependency cannot be excluded.
Conversely, the augmented response to BMP-7 in OVX frac-
tures suggests that the oestrogen-deprived bone environment
may in fact increase sensitivity to BMP-7. Finally, our results
using BMP-7 + ZA further validates adoption of the anabol-
ic—anti-catabolic paradigm in optimizing pharmacological
interventions of the regenerative process.
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